If handled well, the offer could be a positive for several reasons:
1. The company will get the attention of institutions
2. Shares may be placed in "strong hands"
3. The funds can be used to create much greater value by moving some of their pipeline into development
4. Big Pharma will see CGEN's ability to develop on their own, thus be pressured to collaborate more quickly
Recall that COB Martin Gerstel holds many shares, so he wants to create value too.
The PPS drop was a knee--jerk reaction to price-in the anticipated offer. "Shoot 1st, ask questions later". We really need to see the offer price and eventual size to assess the fair dilution.
Seymour is an M.D. recipient from the Baylor College of Medicine, class of '65. You may call 713-798-4054 if you wish to confirm.
Teri Buh; has already been discredited along with most of her distortions in that report. It has already been confirmed that Seymour received his medical degree from the prestigious Baylor med school and only cited Columbia as 1 of the places where he received medical training.
NNVC CEO bought shares on the open market last week. There are many reasons for insiders to sell, but only 1 reason to buy - they know good things are coming. Check out the SECINFO web site (Yahoo will not let me post the url).
Ahhh, OK - thanks!
I would not put all my eggs in any 1 basket. But, regarding the initial tox tests, it seems reasonable that initial tests would be conducted by somebody at the company - I would not expect otherwise. But, other tests were performed by independent and well respected Dr. Eva Harris at UC Berkeley. Also, the company has announced other independent testers will be involved, such as Public Health England, Lovelace (LRRI), and Viroclinics of Rotterdam. I don't claim this is a sure thing, but the opportunity for a huge upside justifies a small investment on the part of the small retail investor who reads here. Large investors lile Goldman and Morgan came in last Q and an insider bought $7M - I think they know more than we do. Regardless, the company's success or failure will hinge on whether their science works, not the distortions posted here and on SA.
My only premise in refuting the post from thinking_about_it is that the initial tox tests were NOT all done by employees of NNVC. I merely pointed out the documented past tests and announced future tests involve independent labs. My premise is not fiction.
You wrote: "Hard to find toxicity when the tests haven't been confirmed by anyone who doesn't work for the company."
This is not factual. You seem to get away with conjuring up falsehoods to suit your bear case without being challenged. There have been studies with over 5000 animals conducted by Dr. Eva Harris (UC Berkeley), Public Health England, Lovelace (LRRI), and Viroclinics of Rotterdam (where the latter initiated the request). None of these parties had any prior relationship with NNVC.
Sentiment: Strong Buy
These insider sales were part of a 10b5-1 plan established months ago when the price was much lower. In Hart's case, he was forced to sell expiring options - that's a no-brainer. Pease sold a small amount of 1 specific option grant, and the 41,000 shares you referenced only pertains to this 1 grant of many he has (so he has no need to buy more on the open market). This is a typical method for insiders to manage their stock option compensation (i.e "cash-in" part of their pay) without being able to act on inside information since the sales are pre-arranged at a specific price (if attained) or specific date long in advance of the actual sale. So, this is not a case of insiders dumping. I get stock options from my company and I always sell them - not because I have inside info portending doom, but because I see them as part of my pay.
Sentiment: Strong Buy
While I am not suggesting anybody is actively pursuing an acquisition of EZCH, I think Intel would be a great potential acquirer. Intel has the capital and existing operations and prior experience in Israel. With their in-house fab, they can produce the chips at lower cost and progress to more advanced processes (i.e. 22nm and 14nm). The NPU would fill a hole in their product suite. Most importantly, the NPS has been shown to far outperform Intel CPUs at SDN data plane functions, so getting the NPS would enable Intel to dominate both the control plane and data plane in future SDN & NFV networks. But, Eli would not sell at any reasonable price, so it is not likely, IMO
Thanks for sharing your insight. The presentation has been posted to the company's website under the Investor section. It was very impressive.
Total revenue for the third quarter of 2013 was $9.1 million. Revenue was up 77% sequentially and up 148% compared to the third quarter of 2012. During the third quarter of 2013, new product revenue increased 131% sequentially to $7.1 million.
So, I told Stealing_Money he had been right so far about QUIK, but would be come back and admit they had turned things around if they proved it?
October 29, 2013
Novadaq Announces Closing of its Previously Announced Bought Deal of Common Shares
TORONTO, ONTARIO--(Marketwired - Oct. 29, 2013) - Novadaq(R) Technologies Inc. ("Novadaq" or the "Company") (TSX:NDQ)(NASDAQ:NVDQ), a developer of real-time medical imaging systems for use in the operating room, announced today the closing of its previously announced sale of 6,250,000 common shares, on a bought deal basis, at a price to the public of $16.75 per common share, pursuant to an underwriting agreement with Piper Jaffray & Co.
Gross proceeds from the offering were approximately US$104.7 million. After the underwriting commissions and other offering expenses, Novadaq received net proceeds of approximately US$99.0 million. Piper Jaffray & Co. acted as sole manager for the offering. The common shares described above were sold by the Company in the United States pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission and were not offered for sale or distributed in any province or territory in Canada.
assets. The Company currently has no present understandings, commitments or agreements to enter into any acquisitions or make any investments.